Phase II study of tiazofurin (NSC 286193) in the treatment of advanced small cell bronchogenic carcinoma.
Fourteen evaluable patients with small cell bronchogenic carcinoma received tiazofurin, an inhibitor of inosine monophosphate dehydrogenase, that progressed after one combination chemotherapy. No objective remission was observed at the dosage of 800 mg/m2 for 5 consecutive days. Toxicity was moderate.
Holoye
P Y
PY
Department of Medical Oncology, University of Texas M.D. Anderson Hospital and Tumor Institute, Houston 77030.
Carr
D T
DT
Dhingra
H M
HM
Glisson
B S
BS
Lee
J S
JS
Murphy
W K
WK
Umsawasdi
T
T
Jeffries
D
D
D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D002283:Carcinoma, Bronchogenic / Q000188:drug therapy*; D018288:Carcinoma, Small Cell / Q000188:drug therapy*; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D012254:Ribavirin / Q000009:adverse effects / Q000031:analogs & derivatives / Q000627:therapeutic use*; D012263:Ribonucleosides / Q000627:therapeutic use*
D000970:Antineoplastic Agents; D012263:Ribonucleosides; D012254:Ribavirin; C033706:tiazofurin